

Post-translational Protein Modification: Novel Technologies and Implications for Cancer Prevention Workshop

Issues to be Discussed

1. **Public and Private Partnership: Discovery and Incentives**
 - Examples of major successes of such partnership? Lessons learned?
 - What were the major barriers that were resolved successfully? Examples?
 - What is the expectation of industry, academia, or government in forging partnership? What are the major concerns or obstacles: What types of incentives would bring all these parties together? Provide some examples.
 - Given the current Intellectual Property regulations, how do we come to an understanding for building partnership? What kind of a framework for understanding each partner gains without putting one a strategic advantage over another?
 - What are the areas in discovery of reagents and tools that are of interest to partners? Pre-competitive science? Technology? Resources?
2. **Public and Private Partnership: Access to Resources and Infrastructure**
 - What kind of mechanism(s) would assist or strengthen collaboration for formal partnering with respect to the development of the necessary infrastructure?
 - Identify opportunities in cancer detection and diagnosis for industry to interact with and where appropriate, co-fund the development of the required infrastructure.
 - Suggest linkages between the private and public, particularly the NCI Early Detection Research Network
3. **Public and Private Partnership: Potential Agreement Models**
 - CRADA under which funding would flow from corporate CRADA collaborators to the NCI Supported Program
 - Gift Funds: provided to the NCI by corporate or private foundation members to support the assigned activities; subject to approval by NCI/NIH
 - A Consortium Chair's Fund (Steering Committee) through which the corporate/foundation members would directly fund the non-NCI portion of the project?